BLOOMFIELD, Conn., July 10, 2023 /PRNewswire/ -- The Cigna Group (NYSE: CI) today released its 2022 environmental, social, and governance (ESG) report outlining the organization's commitment to transforming the ecosystem of health into one that is sustainable, accessible, and equitable—advancing better health for all.
"Driven by our purpose, we approach today's global health challenges with urgency, optimism and a confidence that we will continue to make a positive impact. This year's publication, which is our 10th annual report, is a reflection of the passion and hard work that our colleagues around the world do each and every day," said Nancy Ryan, global ESG lead at The Cigna Group. "While our efforts are ongoing, this report celebrates the goals we've met and inspires us to do even more as we build a healthier world for all."
The Cigna Group's ESG framework is built on four pillars: Healthy Society, Healthy Workforce, Healthy Environment, and Healthy Company. The following are just a few examples of the work being done across the organization to improve the health and environmental outcomes of our communities and customers:
In addition to reporting on the organization's progress to date, this year's report also includes key performance indicators that will be disclosed in future reports for each of area of focus to help demonstrate additional progress.
About The Cigna Group
The Cigna Group (NYSE:CI) is a global health company committed to creating a better future built on the vitality of every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. The Cigna Group includes products and services marketed under Cigna Healthcare, Evernorth Health Services or its subsidiaries. The Cigna Group maintains sales capabilities in more than 30 countries and jurisdictions, and has approximately 190 million customer relationships around the world. Learn more at thecignagroup.com.
Media Contact
Meaghan MacDonald
(860) 840-1212
This email address is being protected from spambots. You need JavaScript enabled to view it.

| Last Trade: | US$274.70 |
| Daily Change: | 2.44 0.90 |
| Daily Volume: | 1,716,450 |
| Market Cap: | US$73.380B |
October 30, 2025 June 12, 2025 | |

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load